Brief: Inhibikase Therapeutics Reports Q1 2022 Results
16/05/2022 22:09
May 16 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS FIRST QUARTER 2022
FINANCIAL
RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* INHIBIKASE THERAPEUTICS - EXPECTS CASH & CASH EQUIVALENTS
SUFFICIENT TO FUND OPERATING EXPENSES & CAPITAL EXPENDITURE
REQUIREMENTS INTO Q3 OF 2023
* INHIBIKASE THERAPEUTICS INC - NET LOSS FOR QUARTER ENDED
MARCH
31, 2022, WAS $0.18 PER SHARE
Source text for Eikon: ID:nPn51H2j6a
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary